EirGen Pharma Oncology Product Eir-047 submitted in US

EirGen Pharma are pleased to announce that their oncology molecule "Eir-047" was submitted to the Food & Drug Admininstration (FDA) in Dec 2008. This product was successful developed as a treatment for early stage breast cancer and passed its fed and fasted clinical trial in the US in Q3 2008.

Technical Director Tom Brennan stated that "we are delighted with this ANDA submission to the FDA as it shows our commitement to developing robust oncology products for global markets". Managing Director Patsy Carney stated that "this is another key milestone for the company and gives us a sound platform from which to launch our oncology franchise in key markets."

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.